Oluyemi Okupe Sells 269,739 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total value of $196,965.28.
• On Friday, September 20th, Oluyemi Okupe sold 12,651 shares of Hims & Hers Health stock. The shares were sold at an average price of $16.79, for a total transaction of $212,410.29.
• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $0.44 during midday trading on Wednesday, hitting $22.36. 8,472,897 shares of the stock traded hands, compared to its average volume of 8,218,643. The business’s 50 day moving average price is $16.58 and its two-hundred day moving average price is $17.47. The firm has a market capitalization of $4.80 billion, a PE ratio of -2,290.00 and a beta of 1.06. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same quarter last year, the business earned ($0.03) earnings per share. Hims & Hers Health’s revenue was up 51.8% compared to the same quarter last year. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Carnegie Investment Counsel acquired a new stake in Hims & Hers Health during the third quarter valued at approximately $5,531,000. Diversify Advisory Services LLC acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at $701,000. Sei Investments Co. increased its stake in Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares in the last quarter. Quantbot Technologies LP raised its holdings in Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after buying an additional 208,621 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Bank of America upped their price target on shares of Hims & Hers Health from $20.00 to $23.00 and gave the company a “buy” rating in a report on Monday. TD Cowen raised their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group lifted their price target on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.07.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.